- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CMS Issues New Reimbursement Code for PSMA PET Agent POSLUMA
The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
The Centers for Medicare and Medicaid Services (CMS) has reportedly issued a pass-through payment reimbursement code for flotufolastat F 18 (POSLUMA, Blue Earth Diagnostics).
Set to go into effect on October 1, 2023, the reimbursement code may facilitate increased access for Medicare beneficiaries to the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent for prostate cancer imaging.
Approved by the Food and Drug Administration (FDA) in May 2023, POSLUMA is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer and suspected metastasis who are candidates for initial definitive treatment, as well as cases involving suspected prostate cancer recurrence for men with elevated prostate-specific antigen (PSA) levels.
“We are very pleased that CMS has granted pass-through status for POSLUMA, as it increases patient access to our innovative product to inform patient management,” said David E. Gauden, D.Phil., the chief executive officer of Blue Earth Diagnostics. “POSLUMA provides physicians with high-quality diagnostic information based on its diagnostic performance even at low PSA levels, high-affinity PSMA binding and potential for low urinary bladder activity.”
In a recent interview at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, Philip Kuo, M.D., Ph.D., FACR, noted phase 3 findings from the SPOTLIGHT and LIGHTHOUSE trials that showed in 96 percent of a 712-patient cohort, the use of POSLUMA enabled clinicians to clearly distinguish between urinary activity and disease uptake with prostate cancer.
“In the vast majority of the cases, urinary activity (with flotufolastat F 18) is low enough in the ureters and bladder that we think it will not potentially affect your ability to detect disease in the pelvis,” noted Dr. Kuo, a professor of medical imaging, biomedical engineering, and medicine at the University of Arizona College of Medicine.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC
January 24th 2025Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
